targetsTarget

SLAMF7 (CS1)

A surface protein found on myeloma cells and on natural killer cells. Elotuzumab tags myeloma cells with it while also switching on the natural killer cells that carry it.

SLAMF7, also known as CS1 or CD319, is a signalling lymphocyte activation molecule family receptor expressed at high levels on malignant plasma cells and on natural killer cells, with little expression on other normal tissues. Elotuzumab, a humanised antibody against SLAMF7, marks myeloma cells for antibody-dependent cellular cytotoxicity and directly activates natural killer cells through the same receptor. It has no single-agent activity but improves outcomes with lenalidomide or pomalidomide plus dexamethasone, the basis of its 2015 and 2018 approvals.

SLAMF7 (CS1): what it is and how drugs act on it · animated generic schematic, not to scale

Target · the protein and the cell it sits on
Drug · antibody, small molecule, cell or radioligand
Effect · signal, damage or kill

In plain words · A surface protein found on myeloma cells and on natural killer cells. Elotuzumab tags myeloma cells with it while also switching on the natural killer cells that carry it.

1 · What it is
A surface protein found on myeloma cells and on natural killer cells. Elotuzumab tags myeloma cells with it while also switching on the natural killer cells that carry it.
2 · What goes wrong in cancer
SLAM family receptor signalling through EAT-2 in natural killer cells; highly expressed on plasma cells and myeloma cells.
3 · How drugs use it
No product in this corpus aims at SLAMF7 (CS1) yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.